Predialysis Vitamin D receptor activator treatment and cardiovascular events after dialysis initiation

A multicenter observational study

Daijo Inaguma, Akihito Tanaka, Hibiki Shinjo, Akiko Kato, Minako Murata

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Vitamin D receptor activator (VDRA) administration has been linked with a reduced incidence of cardiovascular disease (CVD). However, it is unclear whether VDRA administration during the predialysis stage is associated with CVD incidence after dialysis initiation in patients with chronic kidney disease. Therefore, we examined the association between VDRA use and CVD events. Methods: This multicenter observational study included 1,516 patients; they were divided into 2 groups: those who did and did not receive oral VDRA for at least 3 months before dialysis initiation. The CVD incidence was compared between these groups. Factors that impacted CVD incidence were extracted through a multivariate analysis. Subgroups were created based on prior CVD history and serum CRP levels. Results: The incidence of CVD was significantly lower in the VDRA group (log-rank test, p = 0.014). Stepwise multivariate analyses identified age, gender, diabetes, CVD history, calcium-channel blockers, beta-blockers, loop diuretics, anti-platelet agents, phosphate binders, VDRA, erythropoiesis stimulating agents, and cardiothoracic ratio as factors affecting CVD incidence. In the group with no CVD history, VDRA use was associated with a low incidence of CVD (HR 0.35). In the group with serum CRP levels <1.0 mg/dl, VDRA use was associated with a low incidence of CVD (HR 0.47). Conclusion: Administration of VDRA during predialysis was associated with a low incidence of CVD onset after dialysis initiation.

Original languageEnglish
Pages (from-to)35-43
Number of pages9
JournalNephron
Volume133
Issue number1
DOIs
Publication statusPublished - 01-06-2016
Externally publishedYes

Fingerprint

Calcitriol Receptors
Multicenter Studies
Observational Studies
Dialysis
Cardiovascular Diseases
Incidence
Therapeutics
Multivariate Analysis
Hematinics
Sodium Potassium Chloride Symporter Inhibitors
Calcium Channel Blockers
Serum
Chronic Renal Insufficiency

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Urology
  • Physiology (medical)

Cite this

Inaguma, Daijo ; Tanaka, Akihito ; Shinjo, Hibiki ; Kato, Akiko ; Murata, Minako. / Predialysis Vitamin D receptor activator treatment and cardiovascular events after dialysis initiation : A multicenter observational study. In: Nephron. 2016 ; Vol. 133, No. 1. pp. 35-43.
@article{bee5846d606741819003fbb03b22f23e,
title = "Predialysis Vitamin D receptor activator treatment and cardiovascular events after dialysis initiation: A multicenter observational study",
abstract = "Background: Vitamin D receptor activator (VDRA) administration has been linked with a reduced incidence of cardiovascular disease (CVD). However, it is unclear whether VDRA administration during the predialysis stage is associated with CVD incidence after dialysis initiation in patients with chronic kidney disease. Therefore, we examined the association between VDRA use and CVD events. Methods: This multicenter observational study included 1,516 patients; they were divided into 2 groups: those who did and did not receive oral VDRA for at least 3 months before dialysis initiation. The CVD incidence was compared between these groups. Factors that impacted CVD incidence were extracted through a multivariate analysis. Subgroups were created based on prior CVD history and serum CRP levels. Results: The incidence of CVD was significantly lower in the VDRA group (log-rank test, p = 0.014). Stepwise multivariate analyses identified age, gender, diabetes, CVD history, calcium-channel blockers, beta-blockers, loop diuretics, anti-platelet agents, phosphate binders, VDRA, erythropoiesis stimulating agents, and cardiothoracic ratio as factors affecting CVD incidence. In the group with no CVD history, VDRA use was associated with a low incidence of CVD (HR 0.35). In the group with serum CRP levels <1.0 mg/dl, VDRA use was associated with a low incidence of CVD (HR 0.47). Conclusion: Administration of VDRA during predialysis was associated with a low incidence of CVD onset after dialysis initiation.",
author = "Daijo Inaguma and Akihito Tanaka and Hibiki Shinjo and Akiko Kato and Minako Murata",
year = "2016",
month = "6",
day = "1",
doi = "10.1159/000445507",
language = "English",
volume = "133",
pages = "35--43",
journal = "Nephron",
issn = "1660-8151",
number = "1",

}

Predialysis Vitamin D receptor activator treatment and cardiovascular events after dialysis initiation : A multicenter observational study. / Inaguma, Daijo; Tanaka, Akihito; Shinjo, Hibiki; Kato, Akiko; Murata, Minako.

In: Nephron, Vol. 133, No. 1, 01.06.2016, p. 35-43.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predialysis Vitamin D receptor activator treatment and cardiovascular events after dialysis initiation

T2 - A multicenter observational study

AU - Inaguma, Daijo

AU - Tanaka, Akihito

AU - Shinjo, Hibiki

AU - Kato, Akiko

AU - Murata, Minako

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Vitamin D receptor activator (VDRA) administration has been linked with a reduced incidence of cardiovascular disease (CVD). However, it is unclear whether VDRA administration during the predialysis stage is associated with CVD incidence after dialysis initiation in patients with chronic kidney disease. Therefore, we examined the association between VDRA use and CVD events. Methods: This multicenter observational study included 1,516 patients; they were divided into 2 groups: those who did and did not receive oral VDRA for at least 3 months before dialysis initiation. The CVD incidence was compared between these groups. Factors that impacted CVD incidence were extracted through a multivariate analysis. Subgroups were created based on prior CVD history and serum CRP levels. Results: The incidence of CVD was significantly lower in the VDRA group (log-rank test, p = 0.014). Stepwise multivariate analyses identified age, gender, diabetes, CVD history, calcium-channel blockers, beta-blockers, loop diuretics, anti-platelet agents, phosphate binders, VDRA, erythropoiesis stimulating agents, and cardiothoracic ratio as factors affecting CVD incidence. In the group with no CVD history, VDRA use was associated with a low incidence of CVD (HR 0.35). In the group with serum CRP levels <1.0 mg/dl, VDRA use was associated with a low incidence of CVD (HR 0.47). Conclusion: Administration of VDRA during predialysis was associated with a low incidence of CVD onset after dialysis initiation.

AB - Background: Vitamin D receptor activator (VDRA) administration has been linked with a reduced incidence of cardiovascular disease (CVD). However, it is unclear whether VDRA administration during the predialysis stage is associated with CVD incidence after dialysis initiation in patients with chronic kidney disease. Therefore, we examined the association between VDRA use and CVD events. Methods: This multicenter observational study included 1,516 patients; they were divided into 2 groups: those who did and did not receive oral VDRA for at least 3 months before dialysis initiation. The CVD incidence was compared between these groups. Factors that impacted CVD incidence were extracted through a multivariate analysis. Subgroups were created based on prior CVD history and serum CRP levels. Results: The incidence of CVD was significantly lower in the VDRA group (log-rank test, p = 0.014). Stepwise multivariate analyses identified age, gender, diabetes, CVD history, calcium-channel blockers, beta-blockers, loop diuretics, anti-platelet agents, phosphate binders, VDRA, erythropoiesis stimulating agents, and cardiothoracic ratio as factors affecting CVD incidence. In the group with no CVD history, VDRA use was associated with a low incidence of CVD (HR 0.35). In the group with serum CRP levels <1.0 mg/dl, VDRA use was associated with a low incidence of CVD (HR 0.47). Conclusion: Administration of VDRA during predialysis was associated with a low incidence of CVD onset after dialysis initiation.

UR - http://www.scopus.com/inward/record.url?scp=84964059133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964059133&partnerID=8YFLogxK

U2 - 10.1159/000445507

DO - 10.1159/000445507

M3 - Article

VL - 133

SP - 35

EP - 43

JO - Nephron

JF - Nephron

SN - 1660-8151

IS - 1

ER -